News
CABA
2.130
+13.90%
0.260
Weekly Report: what happened at CABA last week (1118-1122)?
Weekly Report · 8h ago
Cabaletta Bio Reports Q3 2024 Financial Results
TipRanks · 6d ago
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Benzinga · 6d ago
Cabaletta Bio announces updated clinical data on CABA-201
TipRanks · 11/18 12:41
Cabaletta Bio’s Promising Clinical Data on CABA-201
TipRanks · 11/18 12:26
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
Benzinga · 11/18 12:11
Weekly Report: what happened at CABA last week (1111-1115)?
Weekly Report · 11/18 09:01
Cabaletta Bio’s RESET Trial Shows Promising Results in Autoimmune Disease Treatment, Supporting Buy Rating
TipRanks · 11/18 08:55
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
Dow Jones · 11/15 19:23
Cabaletta Bio Price Target Cut to $12.00/Share From $20.00 by Wells Fargo
Dow Jones · 11/15 19:23
Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $12
Benzinga · 11/15 19:13
Cabaletta Bio price target lowered to $12 from $20 at Wells Fargo
TipRanks · 11/15 12:36
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 11/15 12:20
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Benzinga · 11/15 12:11
Cabaletta Bio’s Promising Expansion and Strategic Positioning Earns Buy Rating
TipRanks · 11/15 11:25
CABALETTA BIO, INC. <CABA.O>: WELLS FARGO CUTS TARGET PRICE TO $12 FROM $20
Reuters · 11/15 11:13
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
TipRanks · 11/15 10:31
Strong Momentum and Promising Data Drive Buy Opportunity for Cabaletta Bio’s CABA-201
TipRanks · 11/15 10:29
Based on the provided financial report articles, the title of the article is: "Form 10-Q for the quarterly period ended September 30, 2024" This title indicates that the report is a quarterly report filed with the Securities and Exchange Commission (SEC) by Caballerta Bio, Inc. for the period ended September 30, 2024.
Press release · 11/15 01:24
More
Webull provides a variety of real-time CABA stock news. You can receive the latest news about Cabaletta Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.